Abstract
Background Patients with Parkinson’s disease undergo a loss of melanized neurons in substantia nigra pars compacta and locus coeruleus. There are very few in vivo studies of locus coeruleus pathology in Parkinson’s disease with magnetic resonance imaging. Existing studies have used varying methodologies, and reproducibility has not been established for any approach.
Objectives We used neuromelanin-sensitive magnetic resonance imaging to examine the reproducibility of locus coeruleus and substantia nigra pars compacta degeneration in discovery and validation cohorts.
Methods Two cohorts, discovery and validation, recruited from the Emory Movement Disorders Clinic were scanned on two different magnetic resonance imaging scanners. In cohort 1, imaging data from 19 controls and 22 Parkinson’s disease patients were acquired with a Siemens Trio 3 Tesla scanner using a 2D gradient echo sequence with magnetization transfer preparation pulse. Cohort 2 consisted of 33 controls and 39 Parkinson’s disease patients were scanned on a Siemens Prisma 3 Tesla scanner with a similar imaging protocol. Nigral and locus coeruleus volumes were segmented in both cohorts.
Results Nigral volume (Cohort 1: p=0.0148; Cohort 2: p=0.0011) and locus coeruleus volume (Cohort 1: p=0.0412; Cohort 2: p=0.0056) were significantly reduced in the Parkinson’s disease group as compared to controls in both cohorts.
Interpretation Substantia nigra pars compacta volume and locus coeruleus volume were significantly reduced in Parkinson’s disease compared to controls in both cohorts. This imaging approach robustly detects Parkinson’s disease effects on these structures suggesting its use as a potential diagnostic biomarker of Parkinson’s disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by 1K23NS105944-01A1 (Huddleston) from the National Institutes of Health/National Institute of Neurological Diseases and Stroke, Michael J. Fox Foundation grants (MJFF-010556 and MJFF-010854), and the American Parkinson's Disease Foundation Center for Advanced Research at Emory University (Huddleston).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRBs of Emory University and University of California Riverside gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail: daniel.huddleston{at}emory.edu
Data Availability
All data produced in the present study are available upon reasonable request to the authors
